This content is machine translated Multiple sclerosis Better long-term prognosis thanks to modern treatment options Over the past two decades, the arsenal of disease-modifying therapies for multiple sclerosis (MS) has expanded considerably. This applies in particular to the relapsing-remitting form (RRMS), but the treatment options...…
View Post 7 min This content is machine translated Multiple sclerosis Current treatment management of relapsing-remitting MS Various therapeutic strategies are available for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS), including immunomodulators, immunosuppressants and biologic agents. Although each of these therapies reduces relapse frequency and…
View Post 3 min This content is machine translated Multiple Sclerosis: RRMS Therapy change – strategy for follow-up treatment Until the individually appropriate disease-modifying therapy (DMT) is available, there arein the absence of predictive biomarkers, stepwise optimizations are often necessary, possibly resulting in multiple changes of DMT. To reduce…
View Post 13 min This content is machine translated Multiple sclerosis S1P receptor modulators in RRMS: tailored therapy management Modulation of S1P receptors is an important and interesting therapeutic target in the treatment management of multiple sclerosis due to their functional multifold. Currently, three S1P receptor modulators are available… CME-Test
View Post 13 min This content is machine translated Multiple sclerosis New therapeutic option supports first-line management of RRMS Treatment of MS, the autoimmune disease of the central nervous system that most often leads to disability in young adulthood, has made many small advances over the past two decades,… CME-Test
View Post 4 min This content is machine translated Multiple sclerosis Neurofilament determination in serum – a potential biomarker? Background: Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system and, with a median age of onset of 30 years, the most common disabling disease in…
View Post 5 min This content is machine translated ECTRIMS Hot Topic Session The role of autologous hematopoietic stem cell transplantation in MS. In recent years, impressive results have been published on autologous hematopoietic stem cell transplantation in patients with multiple sclerosis. In a pro-con debate at the 32nd Congress of the European…
View Post 7 min This content is machine translated Multiple Sclerosis Symposium in Bern How to increase the benefit of therapy and minimize the risk? At the Multiple Sclerosis Symposium in Bern, experts took a close look at current symptomatic and disease-modifying therapy. With the rapid advances made in recent years, it is important to…
View Post 5 min This content is machine translated Prevention and symptom management in multiple sclerosis Does a healthy diet help? Can you reduce the risk of developing multiple sclerosis if you always eat a healthy diet? And are patients who already suffer from MS possibly fitter due to a low…
View Post 2 min This content is machine translated Multiple sclerosis Not all basic therapeutics are equally effective In the treatment of multiple sclerosis, various therapeutic options such as immunomodulators, immunosuppressants and monoclonal antibodies are available, but it is largely unclear how their relative mode of action is…
View Post 2 min This content is machine translated Thrust-remitting MS An update on basic oral therapy Several encouraging advances have been made in the treatment of relapsing-remitting multiple sclerosis (MS) in recent years. Thus, the first orally administered substance – fingolimod – now also has a…
